NEWS
undefined

undefined

Jiudian Pharmaceutical successfully passed the GMP compliance inspection of NMPA

Jiudian Pharmaceutical successfully passed the GMP compliance inspection of NMPA

From November 5th to 8th, the Hunan Provincial Drug Administration dispatched three inspectors to conduct a four-day GMP compliance inspection on Jiudian Production Center in strict accordance with the requirements of the Good Manufacturing Practice for Pharmaceuticals (revised in 2010) and other laws and regulations. The inspection scope covered the workshops for granules, oral dry suspensions, oral solution, and tablets.

07

2024

/

11

Jiudian Hongyang's API Lurasidone Hydrochloride Approved for Marketing

Jiudian Hongyang's API Lurasidone Hydrochloride Approved for Marketing

Recently, Jiudian Hongyang's API Lurasidone Hydrochloride (Y20220000780) officially obtained the marketing approval from the CDE, and its registration status was successfully transferred to "A".

05

2024

/

11

Professor Xia Xinhua from Hunan University of Chinese Medicine visited Jiudian Pharmaceutical and conducted training on innovative Chinese medicine research

Professor Xia Xinhua from Hunan University of Chinese Medicine visited Jiudian Pharmaceutical and conducted training on innovative Chinese medicine research

On October 25th, Professor Xia Xinhua from Hunan University of Chinese Medicine visited Jiudian Pharmaceutical to carry out pharmaceutical training on innovative Chinese medicines research. Relevant personnel from R&D Department of the Drug Research Institute and QC Department and Process Department of Jiudian Production Center participated in the training.

30

2024

/

10

Jiudian Pharmaceutical was invited to participate in the summary meeting of Chujitang's charity sale activities to help students

Jiudian Pharmaceutical was invited to participate in the summary meeting of Chujitang's charity sale activities to help students

On October 23th, Chujitang Pharmaceutical Group held a summary meeting for the 8th "Love Flying·School Aid Charity Sale" in 2024. As the chief partner of this charity sale, Jiudian Pharmaceutical was invited to attend the summary meeting. Cao Haiyun, director of Jiudian OTC Division, led team members to attend and carried out a Siwu oral thick paste tasting activity at the event site.

24

2024

/

10

Jiudian Pharmaceuticals Attend CPHI Milan 2024

Jiudian Pharmaceuticals Attend CPHI Milan 2024

From October 8th to 10th, the world's largest professional exhibition for the pharmaceutical industry, CPHI Europe (European Pharmaceutical Raw Materials Exhibition), was held in Milan, Italy. Zhu Jiawen, Director of Business Cooperation Department of Jiudian Pharmaceutical, Fan Pengyun, General Manager of Jiudian Hongyang, and Zeng Ling, Director of International Development Department, led the team to participate in the exhibition, winning wide attention with their rich product lines and R&D innovation capabilities.

17

2024

/

10

Jiudian Pharmaceutical successfully passed the on-site audit of the registration of Compound Glycyrrhizin Tablets

Jiudian Pharmaceutical successfully passed the on-site audit of the registration of Compound Glycyrrhizin Tablets

From October 9th to 12th, Center for Food and Drug Inspection of NMPA dispatched 4 inspectors to conduct on-site inspection of the registration of Compound Glycyrrhizin Tablets at Jiudian Pharmaceutical.

15

2024

/

10

Jiudian Pharmaceutical's 7th anniversary of listing

Jiudian Pharmaceutical's 7th anniversary of listing

On October 10th, 2017, Jiudian Pharmaceutical successfully landed on the Shenzhen Stock Exchange's Growth Enterprise Market, stock code: 300705. Taking the listing as a new opportunity, Jiudian Pharmaceutical strengthens its internal strength and sought a new situation. It has made all-round improvements in the fields of R&D, production, and sales, and startes a new journey of rapid and steady development.

10

2024

/

10

Jiudian Hongyang's API Fenofibrate Choline Approved for Marketing

Jiudian Hongyang's API Fenofibrate Choline Approved for Marketing

On September 30th, Jiudian Hongyang's API fenofibrate choline (Y20230000419) successfully obtained the marketing approval from CDE, and its registration status was officially changed to "A".

09

2024

/

10

< 1...456...9 >

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China     TEL. 0086-731-88220222     

1

Business license

SEO www.300.cn  changsha   Privacy policy